This medicines update is provided by the Veterinary Medicines Directorate (VMD) and lists new active substance, new marketing authorisations and changes to authorisations most relevant to vets.
TABLE 1: New marketing authorisations in April 2025
|
New Marketing Authorisations
|
|
Product name and target species
|
Active substance
|
Authorisation Holder, territory, and distribution category
|
Therapeutic group
|
|
Food Animals
|
|
Censutrim 200 mg/ml + 40 mg/ml Solution for Injection for Cattle, Pigs, Horses, Dogs and Cats
|
Sulfadiazine, Trimethoprim
|
DUGV (UK) Limited
GB, POM-V
|
Antimicrobial
|
See the VMD’s Product Information Database for more information on each of these products. There may be a delay before formal documentation is available for some Northern Ireland products, from the European Medicines Agency.
The timing of the product being placed on the market is an issue for the marketing authorisation holder.
Changes to authorisations most relevant to vets
The changes to authorisations most relevant to vets can be found below. Each product is listed, along with the authorisation holder, distribution category and details of which Summary of Product Characteristics (SPC) sections have been revised/changed.
Changes to the SPC, labels and leaflets may change how the medicines should be used. Details can be found on the VMD’s Product Information Database (PID) here.
Due to ongoing assessments, there may be a delay between the point at which a new change is authorised and the updated SPC being available on the PID. There may also be a delay between the point at which any SPC changes are authorised and implementation in the product literature. Unless you have been advised otherwise, the labelling instructions on the pack which is dispensed should be followed.
Medesedan 10 mg/ml Solution for Injection for Horses and Cattle
CP Pharma Handelsgesellschaft mbH GB & NI POM-V
Multiple extensive updates have been made in relation to the SPC sections; 3.3 Contraindications, 3.5 Special precautions for use; 3.6 Adverse events, 3.7 Fertility, use during pregnancy and lactation, 3.9 Administration in combination with other sedatives and anaesthetics and 3.10 Overdose.
Detogesic 10 mg/ml Solution for Injection for Horses
Vetcare Limited NI POM-V
Multiple extensive updates have been made in relation to the SPC sections; 3.2 Indications, 3.3 Contraindications, 3.5 Special precautions for use, 3.6 Adverse events, 3.7 Fertility, use during pregnancy and lactation, 3.8 Interactions with other medicinal products, 3.9 Administration routes and dosage, 3.10 Overdose and 4.2 and 4.3 Pharmacology.
Vigophos 100 mg / ml + 0.05 mg / ml Solution for Injection for Cattle, Horses and Dogs
Livisto Int'l, S.L. GB & NI POM-V
The veterinary medicinal product is now authorised for use in dogs for supportive treatment and prevention of hypophosphataemia and/or cyanocobalamin (vitamin B12) deficiency. Extensive associated changes have been made to multiple sections of the SPC due to the addition of this new target species.
For more information, contact the VMD at postmaster@vmd.gov.uk